CytoMed Therapeutics Limited Ordinary Shares
Here’s whether CytoMed Therapeutics Limited Ordinary Shares (GDTC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+1.52% over 10 days); RSI 52 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -47.6%; rising volume on a downtrend (distribution, 2.73x avg). Currently 73.1% off its 52-week high. Score: -2/7.
GDTC is trading below its 200-day MA ($1.31) — a key warning sign the longer-term trend is under pressure. An RSI of 52.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -47.6% compares to +16.5% for SPY (trailed the market by 64.1%). The current 73.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.